NOVARTIS AG
Business
Novartis AG is an innovative medicines company engaged in research, development, manufacturing, distribution, marketing and sale of pharmaceutical products across cardiovascular, renal and metabolic; immunology; neuroscience; and oncology therapeutic areas. Key marketed products include Entresto for heart failure, Cosentyx for immunological diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, and Pluvicto for prostate cancer, among others. The company operates through five organizational units: Biomedical Research, Development, Operations, and two commercial units (US and International) serving approximately 120 countries. Revenue is concentrated in the US, Europe, and Asia/Africa/Australasia.
Summary from 20-F filed 2026-02-04
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $13.97B |
| Total assets | $110.95B |
| Total liabilities | $64.40B |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is NOVARTIS AG's CIK number?
NOVARTIS AG's SEC CIK number is 0001114448 (1114448). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find NOVARTIS AG's SEC filings?
All of NOVARTIS AG's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.